Roche begins phase 3 trial of Actemra in COVID-19 pneumonia
Roche is to begin a phase 3 trial of its Actemra/RoActemra as a treatment for patients hospitalised with severe COVID-19 pneumonia, following independent research in China suggesting it may help relieve symptoms. The Swiss pharma said it is working with the FDA to begin a randomised...
pharmaphorum.com